The Memorial Delirium Assessment Scale (MDAS)<\/strong><\/a> is an internationally recognized, clinician-administered psychometric instrument specifically designed to quantify the severity of acute cognitive, neurobehavioral, and neuropsychiatric symptoms characteristic of delirium<\/a>. Originally conceptualized and validated by William Breitbart<\/a> and colleagues (1997) at Memorial Sloan Kettering Cancer Center, the MDAS was engineered to overcome the clinical and psychometric constraints of binary screening tools and lengthy diagnostic inventories. Delirium represents an acute, fluctuating organic brain syndrome marked by disturbances in attention, arousal, cognition, and perception, bearing high morbidity and mortality in hospitalized patients, particularly within palliative oncology, intensive care, and geriatric medicine. The MDAS consists of 10 items, each rated on a 4-point ordinal Likert-type severity scale<\/a> ranging from 0 (none \/ normal) to 3 (severe), yielding a potential aggregate score from 0 to 30. The scale captures four critical symptomatic domains: cognitive failure and attention deficits (reduced level of consciousness, disorientation, short-term memory impairment, impaired digit span, and reduced ability to maintain and shift attention), thought organization (disorganized thinking), neuropsychiatric phenomena (perceptual disturbances and delusions), and behavioral\/neurovegetative dysregulation (decreased or increased psychomotor activity and sleep-wake cycle disturbance).<\/p>\n Extensive psychometric investigations have established that the MDAS exhibits robust internal consistency, with Cronbach\u2019s alpha coefficients<\/a> consistently spanning between .77 and .92 across diverse acute care, intensive care, and palliative settings. Test-retest reliability ranges from .75 to .85, while inter-rater reliability among trained clinicians, psychiatrists, and palliative care specialists frequently surpasses intraclass correlation coefficients (ICC) of .90. Construct validity is supported by strong convergent associations with established diagnostic criteria (e.g., DSM-III-R, DSM-IV, and DSM-5) and parallel assessment metrics, including the Delirium Rating Scale-Revised-98 (DRS-R-98)<\/a> and the Confusion Assessment Method (CAM)<\/a>. Furthermore, clinical cutoff scores of 13 or greater yield optimal sensitivity (70.6% to 80%) and specificity (93.8% to 95%) for diagnostic confirmation in palliative samples, while lower thresholds (such as 7 to 10) provide heightened sensitivity in general geriatric and post-operative environments. Its rapid administration time of approximately 10 to 15 minutes, high responsiveness to pharmacological and non-pharmacological clinical resolution, and robust factor structure make the MDAS a gold-standard instrument for bedside longitudinal monitoring and clinical trial endpoints in neurocognitive research.<\/p>\n Memorial Delirium Assessment Scale, MDAS, delirium severity, acute encephalopathy, cognitive impairment, psycho-oncology, palliative care, psychometrics, neuropsychiatric assessment, rating scale<\/p>\n The Memorial Delirium Assessment Scale was developed by William Breitbart, M.D.<\/strong>, along with multidisciplinary clinical researchers in the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY, USA. Key co-investigators contributing to its initial development, cross-validation, and psychometric operationalization include Barry Rosenfeld, Ph.D.<\/strong>, Mark J. Roth, M.D.<\/strong>, Finny T. Smith, M.A.<\/strong>, Kimberly Cohen, M.D.<\/strong>, Shuster J.L., M.D.<\/strong>, and M.J. Passik, Ph.D.<\/strong> Subsequent methodological and comparative analyses have frequently evaluated the scale alongside tools developed by leading neuropsychiatric delirium scholars, notably Paula T. Trzepacz, M.D.<\/strong> (developer of the Delirium Rating Scale).<\/p>\n Author Institutional Affiliation:<\/em> Delirium is an acute, fluctuating neuropsychiatric syndrome characterized by concurrent disruptions in consciousness, attention, cognitive processing, circadian rhythms, and psychomotor dynamics. In tertiary care hospitals, intensive care units (ICUs), and oncology inpatient units, delirium incidence reaches 20% to 85%, significantly escalating the risk of inpatient mortality, protracted mechanical ventilation, prolonged hospitalization, permanent cognitive decline resembling dementia, and institutionalization. Historically, clinical assessment of delirium was impeded by a dichotomy: instruments were either dichotomous screening checklists\u2014such as the Confusion Assessment Method (CAM)\u2014that indicated the presence or absence of delirium without measuring its magnitude, or comprehensive, research-heavy instruments\u2014such as the original Delirium Rating Scale (DRS)\u2014which required extensive historical collateral information and substantial training, rendering them cumbersome for repeated daily administration at the bedside.<\/p>\n The primary purpose of the Memorial Delirium Assessment Scale is to provide a rapid, objective, clinically feasible, and psychometrically rigorous instrument capable of measuring the severity<\/strong> of delirium symptoms over time. Specifically, the MDAS was engineered to:<\/p>\n Delirium represents an organic brain state characterized by widespread neurochemical, metabolic, and electrophysiological dysregulation across cortical and subcortical neural networks. The construct assessed by the MDAS is multidimensional, encapsulating four core syndromic domains that encompass the phenomenological manifestations outlined in the Diagnostic and Statistical Manual of Mental Disorders<\/em> (DSM-III-R, DSM-IV, and DSM-5). The scale evaluates this construct through 10 distinct, operationalized target areas:<\/p>\n Delirium fundamentally disrupts the ascending reticular activating system (ARAS) and its projections to the thalamus and prefrontal cortex. Item 1 of the MDAS captures this basic substrate by rating the patient\u2019s baseline alertness, awareness of external environmental cues, and spontaneous responsiveness to interpersonal interaction. Impairments manifest along a spectrum from normal environmental engagement to lethargy, obtundation, or hypervigilance wherein the patient cannot spontaneously apprehend their surroundings.<\/p>\n Attention is the psychometric backbone of delirium diagnosis. The MDAS operationalizes attention and cognitive processing across four discrete sub-items:<\/p>\n Item 6 evaluates Disorganized Thinking<\/em>, a hallmark of acute cognitive fragmentation. This construct reflects executive dysfunction, disrupted language processing, and semantic incoherence. Patients demonstrate circumstantiality, tangentiality, loose associations, rambling speech, or completely unintelligible responses when prompted with open-ended, complex clinical questions (e.g., “Describe your current medical condition”).<\/p>\n Psychotic manifestations in delirium emerge from cortical misprocessing and aberrant sensory gating:<\/p>\n The motor and chronobiological domains reflect disruptions in basal ganglia circuitry, brainstem nuclei, and suprachiasmatic hypothalamic timing mechanisms:<\/p>\n The MDAS is anchored in neurobiological, cognitive neuropsychological, and syndromal psychiatric theories of delirium. Structurally and diagnostically, it was built to align directly with the criteria of the American Psychiatric Association\u2019s Diagnostic and Statistical Manual of Mental Disorders<\/a> (DSM-III-R and DSM-IV), while remaining highly concordant with modernized DSM-5 criteria. Delirium theory posits that the clinical syndrome represents the final common neurobehavioral pathway of acute, systemic physiological insults acting upon a vulnerable central nervous system.<\/p>\n The core theoretical premise underlying the MDAS items is the balance between central cholinergic neurotransmission and ascending subcortical monoaminergic activity. Acetylcholine<\/a> plays an indispensable role in maintaining attention, working memory, sensory gating, and rapid REM sleep regulation. Deficits in central cholinergic transmission\u2014whether induced by anticholinergic pharmacology, neurodegenerative cholinergic basal forebrain cell loss, or metabolic failure\u2014directly produce the deficits measured by Items 1 through 5 and Item 10. Conversely, hyperdopaminergic states, often accompanied by dysregulated norepinephrine and serotonin activity, fuel psychomotor agitation, disorganized thought architecture, illusions, and delusions, which are captured by Items 6, 7, 8, and 9.<\/p>\n From a cognitive neuroscience perspective, delirium is theorized as an acute disconnection syndrome characterized by functional breakdown within large-scale neurocognitive networks, notably the Default Mode Network (DMN)<\/a>, the Salience Network<\/a>, and the Central Executive Network. When systemic inflammation (driven by cytokines such as IL-1, IL-6, and TNF-alpha), hypoxia, or metabolic disturbances compromise microvascular integrity and blood-brain barrier function, neural network synchronization falters. Individuals with diminished baseline cognitive reserve<\/a> (such as those with underlying pre-existing dementia or microvascular ischemic brain disease) lack the compensatory capacity to maintain attentional tracking and executive control under stress, resulting in the acute symptomatic cascade measured by the 10 MDAS items.<\/p>\n The psychometric validity of the MDAS has been rigorously substantiated across diverse clinical populations, including cancer inpatients, palliative care units, geriatric rehabilitation services, surgical intensive care units, and consultation-liaison psychiatry settings.<\/p>\n In the seminal validation investigation conducted by Breitbart et al. (1997)<\/a> involving hospitalized advanced cancer patients, MDAS scores were compared across three distinct clinical groups: patients meeting DSM-III-R and DSM-IV diagnostic criteria for delirium (mean MDAS score = 14.88 \u00b1 5.76), patients diagnosed with dementia without delirium (mean score = 7.75 \u00b1 3.86), and intact medical controls with neither diagnosis (mean score = 2.05 \u00b1 1.76). Analysis of variance demonstrated highly significant between-group discrimination (p<\/em> < .0001), demonstrating excellent construct and discriminative validity<\/span>.<\/p>\n Concurrent validity has been verified against established gold-standard instruments:<\/p>\n Receiver operating characteristic (ROC) analyses from the seminal validation sample established that a cutoff score of 13 or higher<\/strong> optimized sensitivity (70.6%) and specificity (93.8%) for identifying delirium against DSM-IV criteria in complex palliative oncology environments. However, cross-cultural and setting-specific investigations have identified alternative optimal thresholds based on the baseline prevalence of cognitive pathology:<\/p>\n The MDAS exhibits exceptional responsiveness to longitudinal clinical resolution. In prospective clinical trials of neuroleptic therapy (e.g., Breitbart et al., 2002; Lawlor et al., 2000), longitudinal MDAS scores tracked significant day-to-day decreases following pharmacological intervention, correlating robustly with the resolution of EEG slowing, improvements in nurse-rated behavioral stability, and patient discharge readiness.<\/p>\n The MDAS possesses strong reliability characteristics across multiple evaluative dimensions, including internal consistency, inter-rater concordance, and short-interval stability.<\/p>\n In the original validation study by Breitbart et al. (1997), the overall scale achieved a Cronbach\u2019s alpha<\/a> of .91, indicating high internal homogeneity among the 10 constituent items. Subsequent international validation studies have replicated these parameters:<\/p>\n Because the scale is clinician-administered, inter-rater reliability is vital. In paired simultaneous independent examinations conducted by psychiatrists, research nurses, and palliative care physicians, the inter-rater reliability of the total score has yielded intraclass correlation coefficients (ICC) and Pearson correlation coefficients ranging from .84 to .96<\/strong> (p<\/em> < .001). Individual item kappa coefficients (\u03ba) generally range from .65 (for subtle subjective items like sleep-wake cycle disruptions inferred from collateral nursing logs) to .92 (for structured performance tasks such as digit span and orientation)<\/span>.<\/p>\n Evaluating test-retest reliability in delirium presents a methodological paradox because delirium is, by definition, a fluctuating syndrome. Nonetheless, within short-interval stability designs (evaluations conducted within 2 to 4 hours under stable pharmacological conditions), test-retest correlations range between .75 and .85<\/strong>. This confirms that measurement variability reflects true biological symptom fluctuation rather than psychometric instability.<\/p>\n Substantial empirical inquiry using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) has examined the latent dimensional architecture of the MDAS. Although initially utilized as a unidimensional summary index of delirium severity, psychometric evaluations repeatedly demonstrate that the scale is best characterized by a multi-dimensional construct comprising 2 to 4 latent factors.<\/p>\n Factor analytical studies across oncology, geriatric, and psychiatric cohorts (e.g., Grassi et al., 2001; Shyamsundar et al., 2009) have predominantly isolated either a two-factor or a three-factor solution:<\/p>\n Structural equation modeling and CFA evaluations demonstrate that multi-factor models yield superior fit compared to a strictly unidimensional structure. In fit evaluations, a two- or three-factor structure consistently generates root mean square error of approximation (RMSEA) values below .06, comparative fit index (CFI) values exceeding .95, and Tucker-Lewis Index (TLI) metrics above .94, confirming strong model parsimony and structural stability across diverse clinical settings.<\/p>\n The structural characteristics, administration protocols, and scoring guidelines for the MDAS are summarized below:<\/p>\n The Memorial Delirium Assessment Scale was originally published in 1997<\/strong> by Dr. William Breitbart and co-workers in the Journal of Pain and Symptom Management<\/em>. The instrument was developed under institutional academic sponsorship at Memorial Sloan Kettering Cancer Center (MSKCC).<\/p>\n Breitbart, W., Rosenfeld, B., Roth, A., Smith, M. J., Cohen, K., & Passik, S. (1997). The Memorial Delirium Assessment Scale. Journal of Pain and Symptom Management<\/em>, 13(3), 128\u2013137. https:\/\/doi.org\/10.1016\/S0885-3924(96)00316-8<\/a><\/p>\n Breitbart, W., Tremblay, A., & Gibson, C. (2002). An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics<\/em>, 43(3), 175\u2013182. https:\/\/doi.org\/10.1176\/appi.psy.43.3.175<\/a><\/p>\n Grassi, L., Caraceni, A., Beltrami, E., Borreani, C., Zamorani, M., & De Conno, F. (2001). Assessing delirium in cancer patients: The Italian versions of the Delirium Rating Scale and the Memorial Delirium Assessment Scale. Journal of Pain and Symptom Management<\/em>, 21(1), 59\u201369. https:\/\/doi.org\/10.1016\/S0885-3924(00)00244-X<\/a><\/p>\n Inouye, S. K., van Dyck, C. H., Alessi, C. A., Balkin, S., Siegal, A. P., & Horwitz, R. I. (1990). Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Annals of Internal Medicine<\/em>, 113(12), 941\u2013948. https:\/\/doi.org\/10.7326\/0003-4819-113-12-941<\/a><\/p>\n Lawlor, P. G., Nekolaichuk, C., Gagnon, B., Mancini, I. L., Pereira, J. L., & Bruera, E. D. (2000). Clinical utility, factor analysis, and further psychometric validation of the Memorial Delirium Assessment Scale in patients with advanced cancer. Cancer<\/em>, 88(12), 2859\u20132867. https:\/\/doi.org\/10.1002\/1097-0142(20000615)88:12<2859::AID-CNCR28>3.0.CO;2-9<\/a><\/span><\/p>\n Shyamsundar, G., Raghuthaman, G., Rajkumar, A. P., & Jacob, K. S. (2009). Validation of the Memorial Delirium Assessment Scale in an Indian general hospital setting. General Hospital Psychiatry<\/em>, 31(6), 565\u2013569. https:\/\/doi.org\/10.1016\/j.genhosppsych.2009.07.003<\/a><\/p>\n Trzepacz, P. T., Baker, R. W., & Greenhouse, J. (1988). A symptom rating scale for delirium. Psychiatry Research<\/em>, 23(1), 89\u201397. https:\/\/doi.org\/10.1016\/0165-1781(88)90037-6<\/a><\/p>\n2. Keywords<\/h2>\n
3. Authors<\/h2>\n
\nDepartment of Psychiatry and Behavioral Sciences
\nMemorial Sloan Kettering Cancer Center
\n1275 York Avenue, New York, NY 10065, USA.
\nCorrespondence regarding the original development has historically been addressed to William Breitbart, M.D., Chairman Emeritus of the Department of Psychiatry and Behavioral Sciences, MSKCC.<\/p>\n4. Purpose<\/h2>\n
\n
5. Psychological Construct<\/h2>\n
1. Level of Arousal and Consciousness<\/h3>\n
2. Cognitive and Attentional Processing<\/h3>\n
\n
3. Organization of Thought Processes<\/h3>\n
4. Perceptual and Neuropsychiatric Phenomena<\/h3>\n
\n
5. Psychomotor and Neurovegetative Regulation<\/h3>\n
\n
6. Theoretical Framework<\/h2>\n
Neurochemical and Neurotransmitter Imbalance Hypothesis<\/h3>\n
Network Connectivity and Cognitive Reserve Models<\/h3>\n
7. Validity<\/h2>\n
Construct and Criterion-Related Validity<\/h3>\n
Convergent and Concurrent Validity<\/h3>\n
\n
Diagnostic Accuracy and Cutoff Scores<\/h3>\n
\n
Sensitivity to Clinical Change<\/h3>\n
8. Reliability<\/h2>\n
Internal Consistency<\/h3>\n
\n
Inter-Rater Reliability<\/h3>\n
Test-Retest Stability<\/h3>\n
9. Factor Analysis<\/h2>\n
Exploratory Factor Solutions<\/h3>\n
\n
\n
\n
Confirmatory Factor Analysis and Model Fit<\/h3>\n
10. Instrument \/ Measurement Tool<\/h2>\n
\n
\n
0<\/code> = None (normal functioning \/ absent symptom)<\/li>\n1<\/code> = Mild (barely noticeable or transient impairment; minimal disruption)<\/li>\n2<\/code> = Moderate (undeniable impairment; interview prolonged but not halted)<\/li>\n3<\/code> = Severe (pronounced disruption; task impossible or marked behavioral interference)<\/li>\n<\/ul>\n<\/li>\n\n
11. Permissions & Fee and Test Year<\/h2>\n
\n
12. References<\/h2>\n